**SUPPLEMENTARY TABLE 2:** Sensitivity analyses for severe acne and risk of breast cancer in the Sister Study

|  |  |  |
| --- | --- | --- |
|  | **Number of included cases** | **Fully adjusteda HR (95% CI)** |
| Original estimate | 3,019 | 1.23 (0.98, 1.54) |
| Adjusting for acne/blemish product use ages 10-13 | 2,878 | 1.21 (0.96, 1.52) |
| Excluding polycystic ovarian syndrome | 2,928 | 1.23 (0.98, 1.56) |
| Excluding prophylactic mastectomies | 3,017 | 1.23 (0.98, 1.54) |
| Adjusting for oophorectomyb | 3,017 | 1.23 (0.98, 1.54) |
| Frequent acne/blemish product use ages 10-13 and severe/cystic acne diagnosis |
| Original estimate | 3,018 | 1.35 (0.97, 1.87) |
| Excluding polycystic ovarian syndrome | 2,927 | 1.35 (0.97, 1.90) |
| Excluding prophylactic mastectomies | 3,016 | 1.35 (0.97, 1.88) |
| Adjusting for oophorectomyb | 3,016 | 1.35 (0.97, 1.87) |

**a**Hazard ratio and 95% confidence interval adjusted for race/ethnicity, participant’s baseline highest educational attainment, age at menarche, body mass index (as a restricted cubic spline), baseline menopausal status, interaction between body mass index and menopausal status, parity, hormonal contraceptive use duration, hormone therapy use, smoking, alcohol use and age at first birth.

bHad both ovaries removed (yes/no).